Cushing's syndrome medical therapy
|
Cushing's syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Cushing's syndrome medical therapy On the Web |
|
American Roentgen Ray Society Images of Cushing's syndrome medical therapy |
|
Risk calculators and risk factors for Cushing's syndrome medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Furqan M M. M.B.B.S[2]
Overview
The medications usually used for the treatment of Cushing's syndrome are Pasireotide, Cabergoline, Ketoconazole and Metyrapone. The choice of medical therapy should be individualized. It is guided by drug efficacy, side effects, individual patient factors, and cost.
Medical therapy
Indications for medical treatment of Cushing's syndrome include:[1]
- Acute complications of hypercortisolism (psychosis, and infection).
- Surgery pretreatment in severe cases if surgery is delayed.
- Hypercortisolism after unsuccessful surgery, while awaiting control from radiotherapy.
- Unresectable or metastatic tumors.
- Hypercortisolism due to an occult ectopic ACTH-producing neuroendocrine tumor.
The medications usually used for the treatment of Cushing's syndrome are:[2]
The choice of medical therapy should be individualized. It is guided by drug efficacy, side effects, individual patient factors, and cost.[3]
Drug regimen
Drug regimens used for the treatment of Cushing's syndrome are: [2]
- Drug regimen 1: Ketoconazole 400–1600 mg per day orally
- Drug regimen 2: Mifepristone 300–1200 mg per day orally
- Drug regimen 3: Metyrapone 0·5–4·5 g per day orally
- Drug regimen 4: Pasireotide 750–2400 μg per day subcutaneously injected
- Drug regimen 5: Cabergoline Up to 7 mg per week orally
- Drug regimen 6: Mitotane 3–5 g per day orally
It is important to remember that the vast majority of cases of Cushing's syndrome are caused by steroid medications (such causes are described as iatrogenic) so a review of medications first, as stopping or reducing the dose can usually resolve the problem.
References
- ↑ van der Pas R, de Herder WW, Hofland LJ, Feelders RA (2012). "New developments in the medical treatment of Cushing's syndrome". Endocr. Relat. Cancer. 19 (6): R205–23. doi:10.1530/ERC-12-0191. PMID 22936543.
- ↑ 2.0 2.1 Lacroix A, Feelders RA, Stratakis CA, Nieman LK (2015). "Cushing's syndrome". Lancet. 386 (9996): 913–27. doi:10.1016/S0140-6736(14)61375-1. PMID 26004339.
- ↑ "Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline | The Journal of Clinical Endocrinology & Metabolism | Oxford Academic".